$1.05
5.45% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

CytomX Therapeutics, Inc. Stock price

$1.05
-0.10 8.70% 1M
-4.08 79.53% 6M
-0.50 32.26% YTD
-0.03 2.78% 1Y
-4.63 81.51% 3Y
-5.25 83.32% 5Y
-11.85 91.86% 10Y
Nasdaq, Closing price Fri, Nov 01 2024
+0.05 5.45%
ISIN
US23284F1057
Symbol
CTMX
Sector
Industry

Key metrics

Market capitalization $82.02m
Enterprise Value $-43.41m
P/E (TTM) P/E ratio 7.54
EV/FCF (TTM) EV/FCF 0.50
EV/Sales (TTM) EV/Sales -0.36
P/S ratio (TTM) P/S ratio 0.69
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 40.24%
Revenue (TTM) Revenue $119.57m
EBIT (operating result TTM) EBIT $13.69m
Free Cash Flow (TTM) Free Cash Flow $-86.29m
Cash position $137.18m
EPS (TTM) EPS $0.14
P/E forward negative
P/S forward 0.82
EV/Sales forward negative
Short interest 7.82%
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a CytomX Therapeutics, Inc. forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
57%
Hold
43%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
120 120
40% 40%
100%
- Direct Costs 2.84 2.84
53% 53%
2%
117 117
47% 47%
98%
- Selling and Administrative Expenses 24 24
3% 3%
20%
- Research and Development Expense 76 76
10% 10%
63%
17 17
157% 157%
14%
- Depreciation and Amortization 2.84 2.84
53% 53%
2%
EBIT (Operating Income) EBIT 14 14
139% 139%
11%
Net Profit 11 11
130% 130%
9%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with ...
Neutral
GlobeNewsWire
3 months ago
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -
Neutral
GlobeNewsWire
5 months ago
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25,...
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 122
Founded 2010
Website www.cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today